Inflammatory protein mediators

Inflammatory protein mediators encompass a diverse group of secreted proteins, including cytokines (such as TNF-α, IL-1, and IL-6) and chemokines, that orchestrate the immune system's response to physiological stress or pathogens (StatPearls, 2023). These proteins function as signaling molecules that bind to specific high-affinity receptors on target cells, triggering intracellular pathways that lead to vasodilation, leukocyte recruitment, and the production of additional inflammatory factors (NIH, 2022). In many chronic diseases, such as rheumatoid arthritis and Crohn's disease, the overproduction of these mediators drives tissue damage and systemic inflammation (Nature Reviews Immunology, 2018). Pharmaceutical strategies focus on neutralizing specific mediators using biologic agents like monoclonal antibodies (e.g., Adalimumab for TNF-α) or blocking their receptors (e.g., Tocilizumab for IL-6R) (PubChem). While effective in controlling inflammation, these therapies can impair the host's ability to fight infections, necessitating careful patient monitoring (PubMed, 2021). Because 'Inflammatory protein mediators' is a broad category rather than a specific molecular target, drug discovery and clinical application are focused on the individual components within this class.

Other names

Pro-inflammatory cytokinesInflammatory markersMediators of inflammationAcute phase reactantsInflammatory signaling proteins

Drugs targeting these mediators generally function by neutralizing the specific protein ligand (e.g., anti-TNF antibodies) or by competitively inhibiting the binding of the ligand to its cognate cell-surface receptor (e.g., IL-1 receptor antagonists), thereby halting the pro-inflammatory signaling cascade (StatPearls: Inflammation).